ClinicalTrials.gg
CompletedNCT04311671Updated Mar 3, 2026Results posted

Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole

A Phase 3 interventional study of Moxidectin and Ivermectin in Onchocerciasis, sponsored by Medicines Development for Global Health. Completed at 2 sites in 2 countries. Open to participants aged 4 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Medicines Development for Global Health · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
12,979
Allocation
Randomized
Ages
4 Years and older
Sex
All
01

Study summary

The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity receiving concomitant albendazole.

02

Conditions studied

  • Onchocerciasis

Browse trials for

03

In context

Onchocerciasis

35 studies on the registry are indexed under Onchocerciasis; 7 are open to participants now.

This study's enrollment of 12,979 is above the median of 216 across 26 interventional studies indexed under Onchocerciasis.

Browse Onchocerciasis studies →

Lead sponsor

Medicines Development for Global Health is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of written , or assent with parental or guardian written consent*
  2. Known O. volvulus skin microfilariae density ≥0 microfilariae/mg skin (participants ≥12 years of age only).
  3. Living in an onchocerciasis endemic area.
  4. Age ≥4 years
  5. All female participants of must commit to the use of a reliable method of until 3 months after administration of product (Month 3). * Expression of 'deliberate objection' will be the basis for assessing assent of children aged ≥ 4 to \<6 years

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breast-feeding.
  2. Any concurrent condition that, in the opinion of the Investigator, would preclude evaluation of response to treatment or would pose undue risk to the participant's health.
  3. Has received ivermectin or oral diethylcarbamazine (DEC) within 30 days of Baseline.
  4. Has received treatment with an agent within the 30 days (or 5 half-lives, whichever is longer) prior to planned investigational product administration.
  5. Known or suspected allergy to ivermectin or moxidectin or their and, in areas with high levels of LF co-endemicity, known or suspected allergy to albendazole and its excipients.
  6. Self-reported planned or ongoing activities within the study period that would make it unlikely that the participant will be available for follow-up examinations.
  7. Infection with Loa loa.
  8. Height \<90 cm.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12,979 participants (actual)

Study arms

  • Experimental
    Moxidectin

    In onchocerciasis endemic areas: Moxidectin 8 mg per oral on Day 0

    Drug: Moxidectin

  • Active comparator
    Ivermectin

    In onchocerciasis endemic areas: Ivermectin treatment with approximately 150 µg/kg per oral determined based on height on Day 0

    Drug: Ivermectin

  • Experimental
    Moxidectin with concomitant Albendazole

    In onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity: Moxidectin 8 mg per oral with concomitant albendazole 400 mg per oral on Day 0

    Drug: Moxidectin · Drug: Albendazole

  • Active comparator
    Ivermectin with concomitant Albendazole

    In onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity: Ivermectin treatment with approximately 150 microgram/kilogram (μg/kg) per oral determined based on height with concomitant albendazole 400 mg per oral on Day 0

    Drug: Ivermectin · Drug: Albendazole

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Treatment Emergent Adverse Events

    Participant incidence rates of treatment emergent adverse events following a single dose of moxidectin versus a single dose of ivermectin will be assessed separately by endemic area. Treatment emergent adverse events may also be pooled across both endemic areas (pooled monotherapy and combination therapies separately for moxidectin and ivermectin), provided a qualitative assessment shows they are similar enough to enable the interpretation of the pooled analysis.

    Time frame: Up to 3 months

07

Results

Posted Feb 5, 2026

Participant flow

Participant flow — Overall Study
MilestoneMoxidectinIvermectinMoxidectin Plus AlbendazoleIvermectin Plus Albendazole
Started642116053959994
Completed639515923891977
Not completed26136817

Outcome measures

PrimaryIncidence and Severity of Treatment Emergent Adverse Events

Participant incidence rates of treatment emergent adverse events following a single dose of moxidectin versus a single dose of ivermectin will be assessed separately by endemic area. Treatment emergent adverse events may also be pooled across both endemic areas (pooled monotherapy and combination therapies separately for moxidectin and ivermectin), provided a qualitative assessment shows they are similar enough to enable the interpretation of the pooled analysis.

Time frame:
Up to 3 months
Reported as:
Number · participants
Incidence and Severity of Treatment Emergent Adverse Events
participantsMoxidectinIvermectinMoxidectin Plus AlbendazoleIvermectin Plus AlbendazoleMoxidectin +/- Albendazole (Pooled)Ivermectin +/- Albendazole (Pooled)
Number of Participants with one or more Treatment Emergent Adverse Events (TEAEs)3467911992881545367
Number of Participants with one or more TEAEs defined as a Mazzotti Reaction1734745598628145
Number of Participants with Severe (Gr 3 or 4) TEAE18566148419
Number of Participants with TEAE defined as Serious18440224
Number of participants with TEAE leading to Death623092
Number of Participants with a TEAE considered Related to Moxidectin or Ivermectin18950576128765178
Number of Participants with a Severe TEAE considered Related to Moxidectin or Ivermectin000000
Number of Participants with a TEAE considered Related to Albendazole00347347
Number of Participants with a Severe TEAE considered Related to Albendazole000000

Adverse events

Collected over Adverse events were collected for all participants daily for 5 days and up to 3 months after treatment. More than 98% of participants completed a Month 3 visit.. Non-serious events are listed at a 0.1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Moxidectin6/6,421 (0.1%)18/6,421 (0.3%)346/6,421 (5.4%)
Ivermectin2/1,605 (0.1%)4/1,605 (0.2%)79/1,605 (4.9%)
Moxidectin Plus Albendazole3/3,959 (0.1%)4/3,959 (0.1%)1,199/3,959 (30.3%)
Ivermectin Plus Albendazole0/994 (0%)0/994 (0%)288/994 (29%)
Moxidectin +/- Albendazole (Pooled)9/10,380 (0.1%)22/10,380 (0.2%)1,545/10,380 (14.9%)
Ivermectin +/- Albendazole (Pooled)2/2,599 (0.1%)4/2,599 (0.2%)367/2,599 (14.1%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventMoxidectinIvermectinMoxidectin Plus AlbendazoleIvermectin Plus AlbendazoleMoxidectin +/- Albendazole (Pooled)Ivermectin +/- Albendazole (Pooled)
EnteritisGastrointestinal disorders1/64211/16050/39590/9941/103801/2599
GastritisGastrointestinal disorders0/64211/16050/39590/9940/103801/2599
Hepatic cirrhosisHepatobiliary disorders0/64211/16050/39590/9940/103801/2599
Complicated malaria or malariaInfections and infestations4/64211/16050/39590/9944/103801/2599
ThrombophlebitisVascular disorders0/64211/16050/39590/9940/103801/2599
Cardiac FailureCardiac disorders2/64210/16050/39590/9942/103800/2599
PolydactylyCongenital, familial and genetic disorders0/64210/16051/39590/9941/103800/2599
Dental cariesGastrointestinal disorders0/64210/16051/39590/9941/103800/2599
PneumoniaInfections and infestations1/64210/16051/39590/9942/103800/2599
CellulitisInfections and infestations0/64210/16051/39590/9941/103800/2599
Most frequent other events
Showing 10 of 44
Most frequent other events
EventMoxidectinIvermectinMoxidectin Plus AlbendazoleIvermectin Plus AlbendazoleMoxidectin +/- Albendazole (Pooled)Ivermectin +/- Albendazole (Pooled)
Pruritis / rash pruritic/ rash/ urticariaSkin and subcutaneous tissue disorders92/642122/1605360/395967/994452/1038089/2599
Malaria / complicated malariaInfections and infestations50/64219/1605232/395966/994282/1038075/2599
HeadacheNervous system disorders84/642121/1605161/395954/994245/1038075/2599
Infections (various, not malaria)Infections and infestations24/64214/160589/395916/994113/1038020/2599
Abdominal pain and/or distensionGastrointestinal disorders11/64210/160562/395920/99473/1038020/2599
DiarrheaGastrointestinal disorders7/64212/160557/395916/99464/1038018/2599
Myalgia / musculoskeletal stiffnessMusculoskeletal and connective tissue disorders9/64212/160539/39597/99448/103809/2599
Influenza-like illness, chills or pyrexiaGeneral disorders2/64210/160538/39598/99440/103808/2599
Cough / AsthmaRespiratory, thoracic and mediastinal disorders15/64213/160537/39598/99452/1038011/2599
Peripheral swelling / swellingGeneral disorders0/64210/160533/39599/99433/103809/2599

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)MoxidectinIvermectinMoxidectin With Concomitant AlbendazoleIvermectin With Concomitant AlbendazoleTotal
<=18 years201546113873404203
Between 18 and 65 years4069106124096108149
>=65 years3378316344627
Age, Continuous
Age, Continuous(years)MoxidectinIvermectinMoxidectin With Concomitant AlbendazoleIvermectin With Concomitant AlbendazoleTotal
Mean30.4 (4 to 93)31.2 (4 to 84)28.5 (4 to 91)28.6 (4 to 96)29.8 (4 to 96)
Sex: Female, Male
Sex: Female, Male(Participants)MoxidectinIvermectinMoxidectin With Concomitant AlbendazoleIvermectin With Concomitant AlbendazoleTotal
Female295472418294705977
Male346788121305247002
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)MoxidectinIvermectinMoxidectin With Concomitant AlbendazoleIvermectin With Concomitant AlbendazoleTotal
Race - Black African64211605395999412979
Region of Enrollment
Region of Enrollment(participants)MoxidectinIvermectinMoxidectin With Concomitant AlbendazoleIvermectin With Concomitant AlbendazoleTotal
Congo, The Democratic Republic of the64211605008026
Côte D'Ivoire0039599944953
Number of Participants with Onchocerca volvulus skin microfilariae (mf)
Number of Participants with Onchocerca volvulus skin microfilariae (mf)(participants)MoxidectinIvermectinMoxidectin With Concomitant AlbendazoleIvermectin With Concomitant AlbendazoleTotal
Overall tested62711568328282611947
Undetectable (skin mf =0)60651509306775111392
Detectable (skin mf>0)2065921575555
Number of participants with LF antigenemia and/or microfilaremia
Number of participants with LF antigenemia and/or microfilaremia(participants)MoxidectinIvermectinMoxidectin With Concomitant AlbendazoleIvermectin With Concomitant AlbendazoleTotal
CFA Positive (Category 1-3) with or without microfilaremia——10723130
CFA negative——31798033982
08

Study locations

2 sites
  • Centre Suisse de Recherches Scientifiques en Coˆte d'Ivoire
    Abidjan, Côte d’Ivoire
  • Centre de Recherche pour les Maladies Tropicales Negligees
    Rethy, Ituri, Democratic Republic of the Congo
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Deidentified individual participant data in the form of data listings and SDTM and ADaM datasets may be available for sharing on application to the Sponsor.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will become available 12 months after publication.

Access criteria: Provision of a methodologically sound and relevant proposal detailing the intended use of the data and relevant ethics approval for the proposed analysis, as applicable.

Data sharing details ↗ · www.medicinesdevelopment.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Sep 2024, 40 months.

Results were first posted in Feb 2026, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2020
First posted
Mar 17, 2020
StartActual
May 3, 2021
Primary completionActual
Sep 27, 2024
CompletionActual
Sep 27, 2024
Results first posted
Feb 5, 2026
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04311671
Lead sponsor
Medicines Development for Global Health
Responsible party
Sponsor
First posted
Mar 17, 2020
Start date
May 3, 2021
Primary completion
Sep 27, 2024
Completion
Sep 27, 2024
Results posted
Feb 5, 2026
Last update
Mar 3, 2026

Study contacts

Tony Ukety, MD, DO, MPH
principal investigator · Centre de Recherche en Maladies Tropicales de l'Ituri
Benjamin Koudou, PhD
principal investigator · Centre Suisse de Recherches Scientifiques en Coˆte d'Ivoire

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Moxidectin · Albendazole

Start the discussion